European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission We conducted a retrospective cohort ...

Rising resistance to clarithromycin and levofloxacin necessitates avoiding these in treatment regimens without susceptibility testing. Bismuth quadruple therapy is recommended for treatment-naive ...

Globally, stomach cancer is on the rise in young people, but new research shows that three-quarters of future cases could be prevented by screening for and treating a common bacterial infection: ...

Please provide your email address to receive an email when new articles are posted on . Concomitant and bismuth quadruple therapies had success rates of nearly 90% for initial treatment of H. pylori.

A new study has found that Helicobacter pylori, or H. pylori, a common bacteria that infects nearly half the global population, could be a major driver of stomach cancer worldwide. Researchers ...

It is something that nearly 36 percent of U.S. adults are infected with at some point. Normally, H. pylori can be treated with antibiotics early on, but when left untreated can lead to detrimental ...

The American Journal of Gastroenterology has published a new guideline on the treatment of Helicobacter pylori (H. pylori) infection. The number one recommendation for treatment-naive patients is ...

A history of Helicobacter pylori infection had a modest but statistically significant association with an increased risk of colorectal cancer (CRC), including fatal CRC, a large retrospective analysis ...

Helicobacter pylori bacteria is considered to be the main cause of gastric cancer, with the infection rate particularly high in the Asia-Pacific region. Approximately 90% of cases are linked to H.

Several Twitter users on Thursday, November 25, took to the micro-blogging site to narrate their experiences with bacteria Helicobacter pylori (H. Pylori). The users observed that H. Pylori seems to ...

An invitation to undergo screening for Helicobacter pylori stool antigen did not reduce rates of gastric cancer incidence or mortality, according to results from a Taiwanese randomized trial. Among ...